Pretransplant comprehensive scores to predict long term graft outcomes
Project Number5R21AI172077-02
Former Number1R21AI172077-01
Contact PI/Project LeaderMAS, VALERIA RAQUEL Other PIs
Awardee OrganizationUNIVERSITY OF MARYLAND BALTIMORE
Description
Abstract Text
Despite the improved short-term outcomes in kidney transplantation (KT), comparable progress in long-term
allograft survival has not been achieved. Chronic allograft dysfunction (CAD) characterized by interstitial fibrosis
and tubular atrophy (IFTA), accounts for one quarter of transplant kidneys lost within 5 years. Preventing kidney
graft dysfunction and loss is a critical unmet need in transplantation. From reported evidence, posttransplant
graft survival is determined by the complex interplay of donor factors, acute peri-transplantation injury, and
kidney transplant recipient factors. We recently reported that the transcriptome of deceased donor kidneys
encompasses a gene signature at the time of KT that predicts long-term graft function. These signatures shed
light on the inherent donor mechanisms responsible for triggering and likely sustaining posttransplant injury.
Furthermore, although a recipient peripheral blood transcriptional signature was recently reported as a predictor
of early acute rejection, the effect of pretransplant KT recipient peripheral blood transcriptional profiles on long-
term outcomes has not been previously tested. Moreover, there are no comprehensive biological markers
from donors and recipients that can be used pretransplant to predict graft outcomes. Given the multifactorial
nature of CAD, our preliminary data, and the gaps in our knowledge, we have the unique ability to fill these unmet
needs by studying the early stressors that lead to kidney graft fibrosis deploying an unbiased comprehensive
approach. Towards this goal, we have already established a cohort with prospective sequential sampling of
kidney allografts. In our studies, donor kidneys were evaluated at pre-implantation and recipient pretransplant
peripheral blood mononuclear cells (PBMCs) were collected. The recipient cohort also includes longitudinal
PBMCs, protocol biopsies, and detailed clinical metadata, allowing for the correlation of gene expression profiles
with histological features and clinical parameters. In this exploratory proposal, we hypothesize that early cellular
and molecular events in the donor kidney trigger local inflammatory responses that, when combined with
recipient immune state, propagate and sustain posttransplant kidney injury leading to graft loss. Specific aims
(SA) include: SA1 (1) Identify kidney transplant recipient preimplantation peripheral blood molecular profiles that
associate with immune activation vs quiescence and determine posttransplant graft function. (2) Discern
longitudinal posttransplant molecular variations in patient's PBMCs that associate with long-term graft function.
SA2 Integrate kidney donor and recipient peripheral blood gene expression profiles in association with
donor/recipient clinical characteristics for constructing a composite score to predict long-term outcomes.
IMPACT: Results of these studies will provide a unique understanding of the early molecular triggers that
determine graft outcomes and ultimately lead to CAD. Novel prognostic biomarkers will enable the early
identification of patients at higher risk for progression to CAD, allowing for the development of new therapeutic
modalities that have the potential to avoid irreversible graft injury and improve long-term outcomes.
Public Health Relevance Statement
Despite the improved short-term outcomes in kidney transplantation (KT), comparable progress in long-term
allograft survival has not been achieved with chronic allograft dysfunction (CAD) accounting for most cases of
graft loss. Results from our proposed studies will provide a unique understanding of the early molecular triggers
that determine graft outcomes and ultimately lead to CAD. Novel prognostic biomarkers will enable the early
identification of patients at higher risk for progression to CAD, such that their use in patient monitoring as well
as the development of new therapeutic modalities targeting our identified molecular triggers have the potential
to avoid irreversible graft injury and improve long-term outcomes in KT recipients.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
188435911
UEI
Z9CRZKD42ZT1
Project Start Date
16-March-2023
Project End Date
28-February-2026
Budget Start Date
01-March-2024
Budget End Date
28-February-2026
Project Funding Information for 2024
Total Funding
$232,512
Direct Costs
$164,603
Indirect Costs
$67,909
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$232,512
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R21AI172077-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21AI172077-02
Patents
No Patents information available for 5R21AI172077-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21AI172077-02
Clinical Studies
No Clinical Studies information available for 5R21AI172077-02
News and More
Related News Releases
No news release information available for 5R21AI172077-02
History
No Historical information available for 5R21AI172077-02
Similar Projects
No Similar Projects information available for 5R21AI172077-02